Endothelial function in patients with newly diagnosed type 2 diabetes receiving early intensive insulin therapy.
Multifactorial intervention is unable to improve endothelial dysfunction/cardiovascular outcome in type 2 diabetes. Intensive insulin therapy improves pancreatic β-cell dysfunction in patients with early stage diabetes. We investigated the effect of intensive insulin therapy on endothelial dysfunction in these patients. One hundred and sixteen patients with newly diagnosed type 2 diabetes and 59 healthy subjects received flow-mediated dilatation (FMD) and von Willebrand factor (vWF) measurement. Diabetic patients were further treated with either multifactorial intervention (group A), or intensive insulin therapy (group B) for 2 weeks. Both FMD and vWF measurement were repeated at the same time. FMD was reassessed 90 days after intervention. Compared with healthy subjects, FMD in diabetic patients was significantly lower (group A: 15.99 ± 7.81 % vs. 25.17 ± 7.12 %, P < 0.01; group B: 16.85 ± 7.30 % vs. 25.17 ± 7.12%, P < 0.01), plasma vWF was significantly higher (group A: 224.34 ± 7.36 U/l vs. 109.69 ± 6.30 U/l, P < 0.01; group B: 219.18 ± 6.92 U/l vs. 109.69 ± 6.30 U/l, P < 0.01). After treatment, there was no significant change of FMD in either group. The vWF did not change after multifactorial intervention (220.96 ± 6.85 U/l vs. 224.34 ± 7.36 U/l, P = 0.49), but significantly decreased after intensive insulin therapy (155.08 ± 11.82 U/l vs. 219.18 ± 6.92 U/l, P = 0.0013). Intensive insulin therapy significantly improves endothelial injury/dysfunction as measured by vWF in early stage type 2 diabetes. Further study is needed to determine whether plasma vWF can help early identification, stratification and management of diabetic endothelial dysfunction.